TISIDB

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein
Domain	PF01839 FG-GAP repeat PF00357 Integrin alpha cytoplasmic region PF08441 Integrin alpha PF00092 von Willebrand factor type A domain
Function	Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin alpha-L/beta-2 is also a receptor for F11R (PubMed:11812992, PubMed:15528364). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity (PubMed:15356110). Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:11812992). Required for generation of common lymphoid progenitor cells in bone marrow, indicating a role in lymphopoiesis (By similarity). Integrin alpha-L/beta-2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590).

> Gene Ontology [ TOP ]
Biological Process	GO:0002263 cell activation involved in immune response GO:0002285 lymphocyte activation involved in immune response GO:0002286 T cell activation involved in immune response GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell GO:0002366 leukocyte activation involved in immune response GO:0006909 phagocytosis GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007159 leukocyte cell-cell adhesion GO:0007160 cell-matrix adhesion GO:0007229 integrin-mediated signaling pathway GO:0030198 extracellular matrix organization GO:0031589 cell-substrate adhesion GO:0042110 T cell activation GO:0043062 extracellular structure organization GO:0043113 receptor clustering GO:0050900 leukocyte migration GO:0051668 localization within membrane GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071593 lymphocyte aggregation GO:0072657 protein localization to membrane GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
Molecular Function	GO:0030369 ICAM-3 receptor activity GO:0046982 protein heterodimerization activity GO:0050839 cell adhesion molecule binding
Cellular Component	GO:0008305 integrin complex GO:0034687 integrin alphaL-beta2 complex GO:0043235 receptor complex GO:0098636 protein complex involved in cell adhesion GO:0098802 plasma membrane receptor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04015 Rap1 signaling pathway hsa04514 Cell adhesion molecules (CAMs) hsa04650 Natural killer cell mediated cytotoxicity hsa04670 Leukocyte transendothelial migration hsa04810 Regulation of actin cytoskeleton
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1474244: Extracellular matrix organization R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-168249: Innate Immune System R-HSA-216083: Integrin cell surface interactions R-HSA-6798695: Neutrophil degranulation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04015 Rap1 signaling pathway
hsa04514 Cell adhesion molecules (CAMs)
hsa04650 Natural killer cell mediated cytotoxicity
hsa04670 Leukocyte transendothelial migration
hsa04810 Regulation of actin cytoskeleton

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1474244: Extracellular matrix organization
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-216083: Integrin cell surface interactions
R-HSA-6798695: Neutrophil degranulation

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ITGAL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ITGAL and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23580577	Lymphoma	Promote immunity	Marked elevations in expression of activation receptors, natural cytotoxicity receptors (NKp30, NKp44), and adhesion molecules (CD11a, ICAM-1) were associated with high tumor-lytic capacity, in both in vitro and in vivo models.

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ITGAL in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ITGAL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.156	0.767
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.496	0.694
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.095	0.925
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.281	0.493
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.34	0.854
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.207	0.93
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.947	0.097
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.424	0.282
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.387	0.798
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.623	0.242
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.547	0.47
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.004	0.985

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ITGAL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	23.8	11.8	12	0.427
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	18.2	4.9	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	0	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	0	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	0	7.9	0.26
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGAL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGAL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGAL. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGAL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ITGAL expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ITGAL and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ITGAL
Name	integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
Aliases	CD11A; LFA1A; CD11 antigen-like family member A; LFA-1 alpha; LFA-1A; antigen CD11A (p180), lymphocyte funct ......
Chromosomal Location	16p13.1-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ITGAL collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ITGAL.

ID	Name	Drug Type	Targets	#Targets
DB00095	Efalizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	11
DB00098	Antithymocyte immunoglobulin (rabbit)	Biotech	CD1A, CD4, CD86, FCGR2B, ITGAL, ITGAV, ITGB1, ITGB3, MR1	9
DB00227	Lovastatin	Small Molecule	HDAC2, HMGCR, ITGAL	3
DB00641	Simvastatin	Small Molecule	HMGCR, ITGAL, ITGB2	3
DB02177	1-Acetyl-4-(4-{4-[(2-Ethoxyphenyl)Thio]-3-Nitrophenyl}Pyridin-2-Yl)Piperazine	Small Molecule	ITGAL	1
DB03932	LFA703	Small Molecule	ITGAL	1
DB04724	(S)-2-((S)-3-ISOBUTYL-2,5-DIOXO-4-QUINOLIN-3-YLMETHYL-[1,4]DIAZEPAN-1YL)-N-METHYL-3-NAPHTALEN-2-YL-PROPIONAMIDE	Small Molecule	ITGAL	1
DB06972	7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile	Small Molecule	ITGAL	1
DB07486	3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline	Small Molecule	ITGAL	1
DB11611	Lifitegrast	Small Molecule	ITGAL	1

Browse ITGAL